Future options for ALK-positive non-small cell lung cancer

Lung Cancer

Volumn 87, Issue 3, 2015, Pages 211-219

  Iacono, Daniela ^a,b   Chiari, Rita ^a   Metro, Giulio ^a   Bennati, Chiara ^a   Bellezza, Guido ^c   Cenci, Matteo ^a   Ricciuti, Biagio ^a   Sidoni, Angelo ^c   Baglivo, Sara ^a   Minotti, Vincenzo ^a   Crinò, Lucio ^a  

^a SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Alectinib; ALK; ALK TKI; Ceritinib; CNS metastases; Crizotinib; Non small cell lung cancer; Targeted therapy

Indexed keywords

2 [[2 (ISOPROPYLSULFONYL)PHENYL]AMINO] 4 [[2 METHOXY 4 [4 (4 METHYL 1 PIPERAZINYL) 1 PIPERIDINYL]PHENYL]AMINO] 1,3,5 TRIAZINE; ALECTINIB; ANAPLASTIC LYMPHOMA KINASE; CARBOPLATIN; CERITINIB; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GANETESPIB; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; PEMETREXED; PF 06463922; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RXDX 101; TSR 011; UNCLASSIFIED DRUG; X 396; [2 [[5 CHLORO 2 [[4 [4 (DIMETHYLAMINO) 1 PIPERIDINYL] 2 METHOXYPHENYL]AMINO] 4 PYRIMIDINYL]AMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

AMINOTRANSFERASE BLOOD LEVEL; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG EXPOSURE; DRUG WITHDRAWAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE FUSION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; IMMUNOHISTOCHEMISTRY; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEXT GENERATION SEQUENCING; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; TREATMENT DURATION; VISUAL DISORDER; VOMITING; WILD TYPE; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE; GENETIC RECOMBINATION; GENETICS; LUNG NEOPLASMS; METABOLISM;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR PROTEIN-TYROSINE KINASES; RECOMBINATION, GENETIC;

EID: 84924079312     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.12.017     Document Type: Review

References (74)

1. Metro G., Crinò L. Novel molecular trends in the management of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 2012, 12:729-732.
2. Shaw A.T., Yeap B.Y., Solomon B.J., Riely G.J., Gainor J., Engelman J.A., et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011, 12:1004-1012.
3. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448:561-566.
4. Kerr K.M. ALK testing in non-small cell lung carcinoma: what now?. J Thorac Oncol 2014, 9:593-595.
5. Koivunen J.P., Mermel C., Zejnullahu K., Murphy C., Lifshits E., Holmes A.J., et al. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res 2008, 14:4275-4283.
6. McDermott U., Iafrate A.J., Gray N.S., Shioda T., Classon M., Maheswaran S., et al. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors. Cancer Res 2008, 68:3389-3395.
7. Gainor J.F., Varghese A.M., Ou S.H., Kabraji S., Awad M.M., Katayama R., et al. ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res 2013, 19:4273-4281.
8. Cancer of the lung and bronchus - SEER fact stat sheet. Available at: [accessed 1.9.14]. http://seer.cancer.gov/statfacts/html/lungb.html.
9. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., Rosso S., Coebergh J.W., Comber H., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.
10. Crystal A.S., Shaw A.T. Variants on a theme: a biomarker of crizotinib response in ALK-positive non-small cell lung cancer?. Clin Cancer Res 2012, 18:4479-4481.
11. Shaw A.T., Yeap B.Y., Mino-Kenudson M., Digumarthy S.R., Costa D.B., Heist R.S., et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009, 27:4247-4253.
12. NCCN clinical practice guidelines in oncology - non-small cell lung cancer version 4.2014. Available at: [accessed 1.9.14]. http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf.
13. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363:1693-1703.
14. Crinò L., Kim D., Riely G.J., Janne P.A., Blackhall F.H., Camidge D.R., et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005. J Clin Oncol 2011, 29(Suppl.):7514. [abstract].
15. Malik S.M., Maher V.E., Bijwaard K.E., Becker R.L., Zhang L., Tang S.W., et al. U.S. Food and Drug Administration approval: crizotinib for treatment of advanced or metastatic non-small cell lung cancer that is anaplastic lymphoma kinase positive. Clin Cancer Res 2014, 20:2029-2034.
16. Shaw A.T., Kim D.W., Nakagawa K., Seto T., Crinó L., Ahn M.J., et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl Med 2013, 368:2385-2394.
17. Solomon B.J., Mok T., Kim D.W., Wu Y.L., Nakagawa K., Mekhail T., et al. First-line crizotinib versus chemotherapy in ALK-positive lung cancer: results of a phase III study (PROFILE 1014). NEJM 2014, 371:2167-2177.
18. Shaw A.T., Kim D.W., Mehra R., Tan D.S., Felip E., Chow L.Q., et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014, 370:1189-1197.
19. Chiari R., Buttitta F., Iacono D., Bennati C., Metro G., Di Lorito A., et al. Dramatic response to crizotinib in ROS1 fluorescent in situ hybridization- and immunohistochemistry-positive lung adenocarcinoma: a case series. Clin Lung Cancer 2014, 15:470-474.
20. Peled N., Palmer G., Hirsch F.R., Wynes M.W., Ilouze M., Varella-Garcia M., et al. Next-generation sequencing identifies and immunohistochemistry confirms a novel crizotinib-sensitive ALK rearrangement in a patient with metastatic non-small-cell lung cancer. J Thorac Oncol 2012, 7:e14-e16.
21. Sun J.M., Choi Y.L., Won J.K., Hirsch F.R., Ahn J.S., Ahn M.J., et al. A dramatic response to crizotinib in a non-small-cell lung cancer patient with IHC-positive and FISH-negative ALK. J Thorac Oncol 2012, 7:e36-e38.
22. Chihara D., Suzuki R. More on crizotinib. N Engl J Med 2011, 364:776-777.
23. Sholl L.M., Weremowicz S., Gray S.W., Wong K.K., Chirieac L.R., Lindeman N.I., et al. Combined use of ALK immunohistochemistry and FISH for optimal detection of ALK-rearranged lung adenocarcinomas. J Thorac Oncol 2013, 8:322-328.
24. Marchetti A., Ardizzoni A., Papotti M., Crinò L., Rossi G., Gridelli C., et al. Recommendations for the analysis of ALK gene rearrangements in non-small-cell lung cancer: a consensus of the Italian Association of Medical Oncology and the Italian Society of Pathology and Cytopathology. J Thorac Oncol 2013, 8:352-358.
25. Teixido C., Karachaliou N., Peg V., Gimenez-Capitan A., Rosell R. Concordance of IHC and RT-PCR for EML4-ALK rearrangements. Transl Lung Cancer Res 2014, 3:70-74.
26. Weickhardt A.J., Aisner D.L., Franklin W.A., Varella-Garcia M., Doebele R.C., Camidge D.R. Diagnostic assays for identification of anaplastic lymphoma kinase-positive non-small cell lung cancer. Cancer 2013, 119:1467-1477.
27. Wynes M.W., Sholl L.M., Dietel M., Schuuring E., Tsao M.S., Yatabe Y., et al. An international interpretation study using the ALK IHC antibody D5F3 and a sensitive detection kit demonstrates high concordance between ALK IHC and ALK FISH and between evaluators. J Thorac Oncol 2014, 9:631-638.
28. LDK378 versus chemotherapy in previously untreated patients with ALK rearranged non-small cell lung cancer. Available at: [accessed 1.9.14]. https://clinicaltrials.gov/ct2/results?term=NCT01828099%26Search=Search.
29. Heuckmann J.M., Balke-Want H., Malchers F., Peifer M., Sos M.L., Koker M., et al. Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants. Clin Cancer Res 2012, 18:4682-4690.
30. Kwak E.L., Camidge D.R., Clark J., Shapiro G.I., Maki R.G., Ratain M.J., et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol 2009, 27(Suppl. 15):3509. [abstract].
31. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung caner: updated results from a phase 1 study. Lancet Oncol 2012, 13:1011-1019.
32. Kim D., Ahn M., Shi Y., Yang P.C., Liu X., De Pas T.M., et al. Updated results of a global Phase II study with crizotinib in advanced Alk positive NSCLC. Ann Oncol 2012, 23(Suppl. 9):402. [abstract].
33. Weickhardt A.J., Scheier B., Burke J.M., Gan G., Lu X., Bunn P.A., et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 2012, 7:1807-1814.
34. Costa D.B., Kobayashi S., Pandya S.S., Yeo W.L., Shen Z., Tan W., et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011, 29:e443-e445.
35. Katayama R., Shaw A.T., Khan T.M., Mino-Kenudson M., Solomon B.J., Halmos B., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012, 4:120ra117.
36. Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickardt A.J., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012, 18:1472-1482.
37. Sasaki T., Koivunen J., Ogino A., Yanagita M., Nikiforow S., Zheng W., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011, 71:6051-6060.
38. Camidge D.R., Doebele R.C. Treating ALK-positive lung cancer - early successes and future challenges. Nat Rev Clin Oncol 2012, 9:268-277.
39. Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363:1734-1739.
40. Steuer C.E., Ramalingam S.S. ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options. Cancer 2014, 120:2392-2402.
41. Heuckmann J.M., Hölzel M., Sos M.L., Heynck S., Balke-Want H., Koker M., et al. ALK mutations conferring differential resistance to structurally diverse ALK inhibitors. Clin Cancer Res 2011, 17:7394-7401.
42. Friboulet L., Li N., Katayama R., Lee C.C., Gainor J.F., Crystal A.S., et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014, 4:662-673.
43. Katayama R., Friboulet L., Koike S., Lockerman E.L., Khan T.M., Gainor J.F., et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor Alectinib. Clin Cancer Res 2014, 5686-5696.
44. Kim S., Kim T.M., Kim D.W., Go H., Keam B., Lee S.H., et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol 2013, 8:415-422.
45. Marsilje T.H., Pei W., Chen B., Lu W., Uno T., Jin Y., et al. Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine (LDK378) currently in phase 1 and phase 2 clinical trials. J Med Chem 2013, 56(14):5675-5690.
46. Kim D.W., Mehra R., Tan S.W., Felip E., Chow L.Q.M., Camidge D.R., et al. Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): results of the ASCEND-1 trial. J Clin Oncol 2014, 32(Suppl. 5):8003. [abstract].
47. LDK378 versus chemotherapy in ALK rearranged (ALK positive) patients previously treated with chemotherapy (platinum doublet) and crizotinib. Available at: [accessed 1.9.14]. https://clinicaltrials.gov/ct2/results?term=NCT01828112%26Search=Search.
48. Sakamoto H., Tsukaguchi T., Hiroshima S., Kodama T., Kobayashi T., Fukami T.A., et al. CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 2011, 19:679-690.
49. Kodama T., Tsukaguchi T., Yoshida M., Kondoh O., Sakamoto H. Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 2014, 351:215-221.
50. Seto T., Kiura K., Nishio M., Nakagawa K., Maemondo M., Inoue A., et al. CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study. Lancet Oncol 2013, 14:590-598.
51. Gadgeel S.M., Gandhi L., Riely G.J., Chiappori A.A., West H.L., Azada M.C., et al. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 2014, 15:1119-1128.
52. ALEX study: a randomized, phase III study comparing alectinib with crizotinib in treatment-naive anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients. Available at: [accessed 1.9.14]. https://clinicaltrials.gov/ct2/show/NCT02075840?term=alectinib+and+nsclc%26rank=1.
53. Gettinger S.N., Bazhenova L., Salgia R., Langer C.J., Gold K., Rosell R., et al. ALK inhibitor AP26113 in patients with advanced malignancies, including ALK+ non-small cell lung cancer (NSCLC): updated efficacy and safety data. Ann Oncol 2014, 25(Suppl.4):1292. [abstract].
54. Maitland M.L., Ou S.H., Tolcher A.W., LoRusso P., Bahceci E., Ball H.A., et al. Safety, activity, and pharmacokinetics of an oral anaplastic lymphoma kinase (ALK) inhibitor, ASP3026, observed in a fast follower phase 1 trial design. J Clin Oncol 2014, 32(Suppl. 5):2624. [abstract].
55. Horn L., Infante J.R., Blumenschein G.R., Wakelee H.A., Arkenau H.T., Dukart G., et al. A phase I trial of X-396, a novel ALK inhibitor, in patients with advanced solid tumors. J Clin Oncol 2014, 32(Suppl. 5):8030. [abstract].
56. De Braud F.G., Pilla L., Niger M., Damian S., Bardazza B., Martinetti A., et al. Phase 1 open label, dose escalation study of RXDX101, an oral pan-trk, ROS1, and ALK inhibitor, in patients with advanced solid tumors with relevant molecular alterations. J Clin Oncol 2014, 32(Suppl. 5):2502. [abstract].
57. Johnson T.W., Richardson P.F., Bailey S., Brooun A., Burke B.J., Collins M.R., et al. Discovery of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a macrocyclic inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) with preclinical brain exposure and broad-spectrum potency against ALK-resistant mutations. J Med Chem 2014, 57:4720-4744.
58. A study of PF-06463922 an ALK/ROS1 inhibitor in patients with advanced non small cell lung cancer with specific molecular alterations. Available at: [accessed 1.9.14]. https://clinicaltrials.gov/ct2/results?term=NCT02134912%26Search=Search.
59. Ou S.H., Jänne P.A., Bartlett C.H., Tang Y., Kim D.W., Otterson G.A., et al. Clinical benefit of continuing ALK inhibition with crizotinib beyond initial disease progression in patients with advanced ALK-positive NSCLC. Ann Oncol 2014, 25:415-422.
60. Browning E.T., Weickhardt A.J., Camidge D.R. Response to crizotinib rechallenge after initial progression and intervening chemotherapy in ALK lung cancer. J Thorac Oncol 2013, 8:e21.
61. Matsuoka H., Kurata T., Okamoto I., Kaneda H., Tanaka K., Nakagawa K. Clinical response to crizotinib retreatment after acquisition of drug resistance. J Clin Oncol 2013, 31:e322-e323.
62. Lee J.O., Kim T.M., Lee S.H., Kim D.W., Kim S., Jeon Y.K., et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J Thorac Oncol 2011, 6:1474-1480.
63. Ren S., Chen X., Kuang P., Zheng L., Su C., Li J., et al. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma. Cancer 2012, 118:5588-5594.
64. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.
65. Pemetrexed disodium with or without crizotinib in treating patients with stage IV non-small cell lung cancer that has progressed after crizotinib. Available at: [accessed 1.9.14]. https://clinicaltrials.gov/ct2/results?term=NCT02134912%26Search=Search.
66. Sequist L.V., Gettinger S., Senzer N.N., Martins R.G., Jänne P.A., Lilenbaum R., et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010, 28:4953-4960.
67. Felip E., Carcereny E., Barlesi F., Gandhi L., Sequist L.V., Kim S.W., et al. Phase II activity of the Hsp90 inhibitor AUY922 in patients with ALK-rearranged (ALK+) or EGFR-mutated advanced non-small cell lung cancer. Ann Oncol 2012, 23(Suppl. 9):438. [abstract].
68. Socinski M.A., Goldman J., El-Hariry I., Koczywas M., Vukovic V., Horn L., et al. A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer. Clin Cancer Res 2013, 19:3068-3077.
69. Sang J., Acquaviva J., Friedland J.C., Smith D.L., Sequeira M., Zhang C., et al. Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer. Cancer Discov 2013, 3:430-443.
70. Costa D.B., Shaw A.T., Ou S.H., Solomon B.J., Riely G.J., Ahn M.J., et al. Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small cell lung cancer and brain metastases in PROFILE 1005 and PROFILE 1007. J Thorac Oncol 2013, 8(Suppl. 2):2932. [abstract].
71. Yamaguchi N., Lucena-Araujo A.R., Nakayama S., de Figueiredo-Pontes L.L., Gonzalez D.A., Yasuda H., et al. Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung Cancer 2014, 83:37-43.
72. Lovly C.M., McDonald N.T., Chen H., Ortiz-Cuaran S., Heukamp L.C., Yan Y. Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer. Nat Med 2014, 20:1027-1034.
73. Ilie M., Long E., Butori C., Hofman V., Coelle C., Mauro V., et al. ALK-gene rearrangement: a comparative analysis on circulating tumour cells and tumour tissue from patients with lung adenocarcinoma. Ann Oncol 2012, 23:2907-2913.
74. Pailler E., Adam J., Barthélémy A., Oulhen M., Auger N., Valent A., et al. Detection of circulating tumor cells harboring a unique ALK rearrangement in ALK-positive non-small-cell lung cancer. J Clin Oncol 2013, 31:2273-2281.